Clin Nucl Med. 2018 Jan;43(1):23-24. doi: 10.1097/RLU.0000000000001893.
Prostate imaging with F-labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC, F-fluciclovine) PET/CT scan (Axumin) was recently approved by the US Food and Drug Administration for men with suspected prostate cancer recurrence based on elevated blood prostate-specific antigen levels following prior treatment. We present a rare case of a 77-year-old man with suspected recurrent prostate cancer with an incidental finding of advanced-stage breast cancer showing different degrees of F-fluciclovine uptake.
使用 F 标记的 1-氨基-3-氟环丁烷-1-羧酸（FACBC，F-氟脲苷）PET/CT 扫描（Axumin）进行前列腺成像，最近获得美国食品和药物管理局批准，可用于先前治疗后血液前列腺特异性抗原水平升高的疑似前列腺癌复发的男性。我们报告了一例罕见的 77 岁男性疑似复发性前列腺癌病例，偶然发现晚期乳腺癌，显示不同程度的 F-氟脲苷摄取。
